EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence S… Read more
EXACT Sciences Corporation (EXAS) - Total Assets
Latest total assets as of December 2025: $5.86 Billion USD
Based on the latest financial reports, EXACT Sciences Corporation (EXAS) holds total assets worth $5.86 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
EXACT Sciences Corporation - Total Assets Trend (1998–2025)
This chart illustrates how EXACT Sciences Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
EXACT Sciences Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
EXACT Sciences Corporation's total assets of $5.86 Billion consist of 26.6% current assets and 73.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.3% |
| Accounts Receivable | $298.65 Million | 5.1% |
| Inventory | $166.20 Million | 2.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $919.92 Million | 15.7% |
| Goodwill | $2.37 Billion | 40.4% |
Asset Composition Trend (1998–2025)
This chart illustrates how EXACT Sciences Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EXACT Sciences Corporation's current assets represent 26.6% of total assets in 2025, a decrease from 90.9% in 1998.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2025, down from 90.9% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 40.4% of total assets.
EXACT Sciences Corporation Competitors by Total Assets
Key competitors of EXACT Sciences Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
EXACT Sciences Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - EXACT Sciences Corporation generates 0.55x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - EXACT Sciences Corporation is currently not profitable relative to its asset base.
EXACT Sciences Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.23 | 2.15 | 2.82 |
| Quick Ratio | 1.97 | 1.92 | 2.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $788.41 Million | $ 839.24 Million | $ 1.15 Billion |
EXACT Sciences Corporation - Advanced Valuation Insights
This section examines the relationship between EXACT Sciences Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.22 |
| Latest Market Cap to Assets Ratio | 3.34 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | $5.86 Billion |
| Market Capitalization | $19.59 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values EXACT Sciences Corporation's assets at a significant premium ( 3.34x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: EXACT Sciences Corporation's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for EXACT Sciences Corporation (1998–2025)
The table below shows the annual total assets of EXACT Sciences Corporation from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.86 Billion | -1.14% |
| 2024-12-31 | $5.93 Billion | -8.39% |
| 2023-12-31 | $6.47 Billion | +3.93% |
| 2022-12-31 | $6.23 Billion | -6.85% |
| 2021-12-31 | $6.68 Billion | +35.73% |
| 2020-12-31 | $4.93 Billion | +40.49% |
| 2019-12-31 | $3.51 Billion | +130.03% |
| 2018-12-31 | $1.52 Billion | +154.61% |
| 2017-12-31 | $598.56 Million | +58.75% |
| 2016-12-31 | $377.04 Million | +3.50% |
| 2015-12-31 | $364.30 Million | +16.90% |
| 2014-12-31 | $311.62 Million | +112.53% |
| 2013-12-31 | $146.63 Million | +30.78% |
| 2012-12-31 | $112.12 Million | +15.64% |
| 2011-12-31 | $96.95 Million | +0.45% |
| 2010-12-31 | $96.52 Million | +274.52% |
| 2009-12-31 | $25.77 Million | +336.93% |
| 2008-12-31 | $5.90 Million | -59.59% |
| 2007-12-31 | $14.60 Million | -38.85% |
| 2006-12-31 | $23.87 Million | -36.93% |
| 2005-12-31 | $37.84 Million | -32.55% |
| 2004-12-31 | $56.11 Million | +61.79% |
| 2003-12-31 | $34.68 Million | -30.76% |
| 2002-12-31 | $50.09 Million | -20.62% |
| 2001-12-31 | $63.10 Million | +117.15% |
| 2000-12-31 | $29.06 Million | +511.26% |
| 1999-12-31 | $4.75 Million | -51.03% |
| 1998-12-31 | $9.71 Million | -- |